iii. Ordinance, Rules and Regulations in the manufacturing of quality

iii. Ordinance, Rules and Regulations in the manufacturing of quality, safety and efficacy of Āyurvedic drugs for the consumers

Introduction and Historical Evolution

Pre-Independence Context

- **Traditional Roots**: Ayurveda, grounded in classical texts like the *Caraka Saṃhitā* and *Suśruta Saṃhitā*, was practiced through lineage-based traditions. Quality control largely relied on the reputation of vaidyas (practitioners) and adherence to textual formulations.
- **Colonial Era**: British regulations primarily targeted allopathic drugs. Indigenous medicines were left relatively unregulated, with only occasional interventions.

Post-Independence Developments

- **Recognition of Ayurveda**: After independence, India began formally recognizing Ayurveda as a distinct healthcare system. Today it is overseen by the Ministry of AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha, and Homoeopathy).
- **Legal Incorporation**: The Drugs and Cosmetics Act (1940) initially focused on allopathic drugs but was progressively amended to cover Ayurvedic, Siddha, and Unani (ASU) medicines. This gave Ayurveda a legal framework and brought standardization processes.

Key Legislative and Administrative Framework

Drugs and Cosmetics Act, 1940 (D&C Act) and Subsequent Amendments

1. **Chapter IVA (1964 Amendment)**
   - Created specific provisions for “Ayurvedic, Siddha, or Unani drugs.”
   - **Section 33E** defines standards for ASU drugs.
   - **Section 33EE** prohibits the manufacture and sale of adulterated, spurious, or misbranded ASU drugs.
2. **Drugs and Cosmetics Rules, 1945**
   - **Part XIV & XIVA** outline regulations for licensing, labeling, and sale of Ayurvedic drugs.
   - **Rule 158-B** mandates adherence to Good Manufacturing Practices (GMP) for ASU drug production.
   - **Rule 161** covers labeling requirements and licensing forms (e.g., Form 24D for manufacturing, Form 25D for sale).
3. **Notable Amendments/Notifications**
   - **2023 Amendment**: Introduced mandatory NDPS (Narcotic Drugs and Psychotropic Substances) compliance for specific herbs (e.g., Cannabis) in Ayurvedic formulations.
   - **2021 Notification**: Expanded *Schedule E(1)* to include more stringent heavy metal limits (e.g., lead ≤10 ppm, arsenic ≤3 ppm) and updated labeling requirements.

Ministry of AYUSH

- **Administrative Oversight**: Formulates policies, funds research, and coordinates regulations for Ayurveda and other traditional systems.
- **Pharmacopoeial Commission for Indian Medicine & Homoeopathy (PCIM&H)**: Publishes the *Ayurvedic Pharmacopoeia of India (API)* and *Ayurvedic Formulary of India (AFI)*, providing official monographs and standardized methodologies.

Other Relevant Regulations

1. **Food Safety and Standards Authority of India (FSSAI)**
   - Relevant when Ayurvedic products border on “nutraceuticals” or “functional foods” with health claims rather than classical therapeutic claims.

2. **Biological Diversity Act (2002)**
    - Governs the sustainable use of medicinal plants and ensures Access and Benefit-Sharing (ABS) if wild resources or traditional knowledge are used.
3. **Patent Laws & TKDL**
    - *Traditional Knowledge Digital Library (TKDL)* is used to prevent the misappropriation (biopiracy) of classical Ayurvedic formulations under new patents.
    - Ensures credit and protection for India's traditional knowledge pool.

Quality Control Mechanisms

Good Manufacturing Practices (GMP)

- **Schedule T of the D&C Rules**: Lays down requirements for premises, equipment, hygiene, raw material storage, documentation, and in-process quality checks.
- **Infrastructure & Staff Qualifications**: Plants must prevent cross-contamination and maintain trained staff well-versed in Ayurvedic processing.
- **Recent Developments**:
    - **Mandatory QR Codes** on packaging (introduced around 2023) for supply-chain traceability and to curb counterfeits.
    - **AI-Driven QC Tools** for predictive analytics (experimental stage in some big manufacturers).

Raw Material Authentication

- **Pharmacopoeial Standards**:
    - *Ayurvedic Pharmacopoeia of India (API)* contains monographs for single drugs and formulations, specifying identity, purity, potency tests.
    - *Ayurvedic Formulary of India (AFI)* standardizes classical formulations (e.g., *Triphala Churna*).
- **Modern Analytical Techniques**:
    - **DNA Barcoding** to ensure correct botanical identity of raw herbs (e.g., *Bacopa monnieri*).
    - **High-Performance Thin Layer Chromatography (HPTLC)** for marker compound profiling (e.g., withanolides in *Ashwagandha*).
    - **Inductively Coupled Plasma Mass Spectrometry (ICP-MS)** or **LC-MS/MS** to check heavy metals (Pb, As, Hg, Cd) and pesticide residues.

Licensing and Compliance

- **State Licensing Authorities (SLAs)**: Primary issuance of manufacturing licenses under Rule 159(4) of the D&C Rules.
- **Central Licensing Authority (CLA)**: Deals with large-scale or interstate manufacturers, ensuring uniformity of enforcement across India.
- **e-AUSHADHI Portal**: A digital platform for licensing, record-keeping, and audits, increasing transparency and compliance efficiency.

Safety Regulations

Toxicity and Contamination Control

- **Schedule E(1)**: Lists potentially toxic or poisonous raw drugs (e.g., *Aconitum ferox*) alongside permissible limits.
- **Heavy Metal and Pesticide Testing**:
    - Metals (lead, arsenic, mercury, cadmium) require rigorous testing, especially for *Rasa Shastra* (bhasma-based) products.
    - Pesticide residue limits often align with international (EU/WHO) benchmarks.
- **Detoxification Protocols**: Classical texts describe *Shodhana (purification)* processes for metals/minerals. Modern regulations demand proof of de-toxification steps.

Pharmacovigilance

- **National Pharmacovigilance Programme for ASU Drugs (launched ~2018)**:
  - Monitors Adverse Drug Reactions (ADR) through specialized centers and the Ayush Safety Monitoring Cell (SAF-CON).
  - Collaboration with the *Pharmacovigilance Programme of India (PvPI)* ensures adverse events are tracked in a shared database.
- **Consumer Awareness and Reporting**: Encouraged for real-world evidence on rare or serious side effects.

Labeling and Consumer Protection

- **Rule 161(3)**: Requires clear labeling in English plus regional languages, indicating:
  - Ingredients (common, Sanskrit, or scientific names), batch number, expiry, dosage instructions, and contraindications.
  - Warning statements (e.g., “For medicinal use only” for Schedule E(1) substances or presence of metals).
- **Allergen Declarations (2022 Update)**: Products containing allergens (e.g., sugar for diabetic patients) must include cautionary labels.

Efficacy Validation

Classical vs. Proprietary Formulations

- **Classical Formulations**: Credibility is often assumed based on authoritative Ayurvedic texts. Licensing requires proof of textual reference plus basic quality tests.
- **Proprietary Formulations**: Must submit additional data—rationale, pilot studies, or in some cases clinical trial results—especially if claiming new therapeutic benefits (e.g., anti-diabetic, immunomodulatory).

Clinical Trials and Research

- **Rule 158-B(3)**: Allows for clinical trials, especially for novel ASU drugs, under guidelines resembling modern-phase trials.
- **CDSCO Guidelines (2020)**: Stipulate proof-of-concept (PoC) data for patent or proprietary medicines. Ethics committee approval (as per ICMR guidelines) is mandatory.
- **Evidence-Based Initiatives**:
  - *CCRAS (Central Council for Research in Ayurvedic Sciences)* undertakes collaborative research (e.g., *Golden Triangle Partnership* with ICMR and CSIR).
  - *Reverse Pharmacology* approach to validate traditional claims (e.g., *Tulsi* in respiratory disorders).

Global Regulatory Harmonization

WHO Benchmarks and ISO Standards

- **WHO Benchmarks for Training in Ayurveda (2019)**: Aims to align educational and practice standards worldwide.
- **ISO/TC 249**: Works on global standardization in traditional medicine, leading to specific standards (e.g., *ISO 23419:2021* for Chyawanprash).

USFDA and EU Compliance

- **USFDA Botanical Drug Pathway**: Investigational New Drug (IND) filings allow clinical trials of Ayurvedic botanicals (e.g., Curcumin C3 Complex).
- **EU Traditional Herbal Medicinal Products Directive (THMPD)**: Demands ~30 years of traditional usage evidence before market approval. Indian companies have used this route for *Triphala* and other well-known formulations.

Other International Examples

- **Japan's Kampo-Ayurveda Synergy**:
  - The Pharmaceuticals and Medical Devices Agency (PMDA) may consider well-documented Ayurvedic data in formulating guidelines for herbal medicines akin to Kampo.

Challenges and Future Directions

Key Challenges

1. **Standardization Variability**: Polyherbal formulations often exhibit batch-to-batch variability in active constituents.
2. **Adulteration & Substitution**: Unscrupulous replacement of rare or expensive herbs with inferior substitutes (e.g., *Senna* instead of *Trivrut*).
3. **Regulatory Capacity**: Limited manpower for on-site inspections, especially in rural-based manufacturing units.

Emerging Innovations

1. **Blockchain for Supply Chain**: Enables end-to-end traceability from farm to pharmacy.
2. **AI-Driven Quality Control**: Predictive modeling to minimize contamination risk, optimize batch consistency.
3. **Good Agricultural & Collection Practices (GACP)**: A push to standardize farming and harvesting, ensuring consistent raw materials.

Policy Recommendations

1. **One Health Integration**: Connect Ayurvedic herbal sourcing with biodiversity conservation.
2. **Global ASU Pharmacopoeia**: Unified standards for export-oriented manufacturers, easing global market entry.
3. **Stricter Post-Marketing Surveillance**: Additional vigilance to identify substandard or spurious products, building consumer trust.

Conclusion

India's regulatory framework for Ayurvedic drugs—rooted in both historical knowledge and modern scientific rigors—continues to evolve. Key statutes like the Drugs and Cosmetics Act (1940) and its subsequent amendments, alongside rules issued by the Ministry of AYUSH, set minimum standards for:

- **Quality**: Stringent GMP (Schedule T), raw material authentication, and advanced analytical methods.
- **Safety**: Comprehensive toxicity checks, heavy metal and pesticide residue limits, and robust pharmacovigilance programs.
- **Efficacy**: Classical references for traditional formulations and clinical trials for novel or proprietary formulations.

Furthermore, the government's increasing focus on international harmonization (WHO benchmarks, ISO standards, USFDA, EU THMPD) underscores Ayurveda's potential for global growth. By embracing modern technologies (DNA barcoding, HPTLC, AI-driven QC) and strengthening supply-chain oversight, the Ayurvedic pharmaceutical sector can ensure consumer trust and meet international quality benchmarks. Balancing tradition with innovation remains the cornerstone of Ayurveda's future trajectory in the global healthcare market.